BLPH实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 03:12):

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States...

Stats
今日成交量	8 136.00
平均成交量	41 765.00
市值	674 016
EPS	$0 ( 2024-03-29 )
下一个收益日期	( $0 ) 2024-06-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0600
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-13	Puissance Capital Management Lp	Sell	1 076 841	Common Stock
2023-06-07	Amin Naseem	Buy	47 578	Common Stock
2023-06-07	Fernandes Peter	Sell	100 000	Stock Options (Right to Buy)
2023-06-07	Shah Parag Suresh	Sell	50 000	Stock Options (Right to Buy)
2023-06-07	Dekker Martin	Sell	50 000	Stock Options (Right to Buy)

INSIDER POWER
-74.15
Last 99 transactions
Buy: 6 532 145 \| Sell: 5 633 542

Bellerophon Therapeutics 相关性

10 最正相关
CPTA	0.936
SGEN	0.934
RETA	0.929
ORTX	0.928
NVCT	0.924
XLRN	0.922
DUOL	0.92
FLMN	0.919
LMB	0.919
RELY	0.918

10 最负相关
CMLS	-0.959
JRJC	-0.949
AADI	-0.947
CPTN	-0.944
MICS	-0.942
IHRT	-0.942
MDRX	-0.942
EYE	-0.941
ESSA	-0.94
SILK	-0.938

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Bellerophon Therapeutics 财务报表

Annual	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-2.08

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-2.08

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.870

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-3.17

Financial Reports:

No articles found.

Bellerophon Therapeutics

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.